Does subclinical hypothyroidism raise LDL cholesterol and atherosclerotic cardiovascular disease risk?

Subclinical hypothyroidism (SCH)—characterized by elevated thyroid-stimulating hormone (TSH) and normal free thyroxine (T4) levels—is an established risk-enhancing factor for dyslipidemia and cardiovascular disease.

Clinical evidence

• Lipid Elevations: Large cohort studies and meta-analyses show that SCH is associated with modest but significant elevations in LDL cholesterol (LDL-C), typically averaging 8 to 15 mg/dL higher than euthyroid controls. This relationship is proportional to TSH levels, with the most pronounced dyslipidemia occurring at TSH thresholds ≥7–10 mIU/L. Levothyroxine therapy reduces LDL-C by approximately 10–11 mg/dL.
• Cardiovascular Risk: SCH is associated with a higher risk of atherosclerotic cardiovascular disease (ASCVD) events, coronary heart disease (CHD) mortality, and stroke. This risk is particularly pronounced in younger patients (under 65 years) and when TSH is ≥10 mIU/L.

Mechanistic pathways

• Reduced Hepatic LDL Clearance: Triiodothyronine (T3) signaling deficiency in the liver impairs the transcription of the LDL receptor (LDLR) and its regulator SREBP-2. This decreases hepatic LDLR expression and activity, leading to reduced clearance of circulating LDL particles. Elevated TSH may also upregulate PCSK9, which accelerates LDLR degradation.
• Vascular Calcification: SCH is independently associated with elevated coronary artery calcium (CAC) scores and carotid intima-media thickness, indicating increased arterial plaque burden, diastolic dysfunction, and endothelial stiffness.

Bottom line

• Subclinical hypothyroidism is a key driver of elevated LDL-C and accelerated ASCVD risk, primarily mediated by impaired hepatic LDLR clearance and vascular calcification. This risk is highly clinically relevant for younger adults under 65 and individuals with TSH levels ≥10 mIU/L.